An oral calcitonin gene-related peptide receptor antagonist for acute migraine management: sign of a possible new chapter in headache medicine.
Garza
Ivan
I
Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55902, USA. garza.ivan@mayo.edu
D000328:Adult; D000368:Aged; D000818:Animals; D001381:Azepines / Q000627:therapeutic use*; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D055815:Young Adult
D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D007093:Imidazoles; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide